Get the Stockscreener App
0.5003
3.42%
-0.0177
After Hours:
.50
-0.0003
-0.06%
Oncolytics Biotech Inc stock is traded at $0.5003, with a volume of 438.88K.
It is down -3.42% in the last 24 hours and down -12.63% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$0.518
Open:
$0.5025
24h Volume:
438.88K
Relative Volume:
1.55
Market Cap:
$46.68M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-1.8915
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
-7.18%
1M Performance:
-12.63%
6M Performance:
-48.95%
1Y Performance:
-56.87%
1-Day Range:
$0.4975
$0.5302
1-Week Range:
$0.4975
$0.54
52-Week Range:
$0.4679
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.5003 | 46.68M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
561.75 | 34.75B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.40 | 33.69B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Stocks in play: Oncolytics Biotech Inc - The Globe and Mail
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Oncolytics Biotech Reports Q1 Results and Clinical Progress - TipRanks
Oncolytics Biotech Reports Q1 2025 Financial Results - TipRanks
Oncolytics Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Oncolytics Biotech Reports Promising Q1 Results and Advances in Cancer Treatment - TipRanks
Breakthrough Cancer Trial: Oncolytics Achieves 33% Response Rate in Anal Cancer, Reports Strong Q1 Progress - Stock Titan
How To Trade (ONC) (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights - Kilgore News Herald
Oncolytics Biotech Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
(ONC) Trading Strategy and Analysis (ONC:CA) - news.stocktradersdaily.com
(ONC) Stock Analysis and Trading Signals (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech to Discuss Q1 2025 Financial Results on May 14 - TipRanks
Stocks In Play: Oncolytics Biotech® Inc. By Baystreet.ca - Investing.com Canada
Oncolytics Biotech® Inc. - Baystreet.ca
Stocks in play: Oncolytics Biotech® Inc. - The Globe and Mail
Oncolytics Biotech to Discuss Q1 Financial Results and Operational Highlights - TipRanks
Oncolytics Biotech® to Host Conference Call to Discuss First Qua - GuruFocus
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights | ONCY Stock News - GuruFocus
(ONC) Risk-Controlled Trading Report (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech(R) and PrECOG Announce Collaboration for BRACELET-1 (PrE0113) Study in Metastatic Breast Cancer - ACCESS Newswire
(ONC) Technical Data (ONC:CA) - news.stocktradersdaily.com
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty - Longview News-Journal
Oncolytics Biotech, Inc. to Host Earnings Call - ACCESS Newswire
(ONC) Technical Patterns and Signals (ONC:CA) - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - ADVFN
(ONC) Stock Trading Blueprint (ONC:CA) - news.stocktradersdaily.com
Small-cap cancer therapy innovator raises $20M in flexible funding - MSN
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Oncolytics to Present New Pancreatic Cancer Data at Oncology Meeting Next Month - marketscreener.com
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at AS - GuruFocus
Oncolytics Biotech to Present Promising Pancreatic Cancer Data at ASCO 2025 - TipRanks
Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action - Barchart.com
(ONC) Long Term Investment Analysis (ONC:CA) - news.stocktradersdaily.com
Investors Eye Biotech Sector as Cancer Therapy Market Surges (PR Newswire) - Aktiellt
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire) - Aktiellt
Buzz on the Bullboards: Energy, cannabis, and Biotech Shine on the TSX | 2025-04-17 | Investing News - Stockhouse
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights - Quantisnow
(ONC) Investment Performance Report (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech : reg; Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer - marketscreener.com
Oncolytic Virus Therapy Market Size, Share and Strategic - openPR.com
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz - The Malaysian Reserve
As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments - Baystreet.ca
Trend Tracker for (ONC) (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers - Eastern Progress
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):